Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOIRAI first-line CLL/SLL fixed-duration versus MRD-guided venetoclax combinations
2023-510294-34-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of venetoclax, obinutuzumab and pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by University of Cologne. Primary endpoint: Progression-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
venetoclaxobinutuzumabpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-510294-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510294-34-00.